NVS vs. GSK
NVS (Novartis AG) and GSK (GSK plc) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 10 years, NVS returned 10.49%/yr vs 3.76%/yr for GSK. Their 0.50 correlation means they have sometimes moved together and sometimes differently.
Performance
NVS vs. GSK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVS achieves a 16.71% return, which is significantly higher than GSK's 7.22% return. Over the past 10 years, NVS has outperformed GSK with an annualized return of 10.49%, while GSK has yielded a comparatively lower 3.76% annualized return.
NVS
- 1D
- -1.45%
- 1M
- -2.35%
- 6M
- 8.22%
- YTD
- 16.71%
- 1Y
- 39.55%
- 3Y*
- 18.79%
- 5Y*
- 15.30%
- 10Y*
- 10.49%
- ALL TIME*
- 9.10%
GSK
- 1D
- -0.73%
- 1M
- -3.67%
- 6M
- 1.90%
- YTD
- 7.22%
- 1Y
- 42.78%
- 3Y*
- 18.53%
- 5Y*
- 4.82%
- 10Y*
- 3.76%
- ALL TIME*
- 8.48%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
GSK GSK plc | $276.89M | $237.83M | $206.74M |
NVS Novartis AG | $287.25M | $275.96M | $277.92M |
NVS vs. GSK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVS Novartis AG | 16.71% | 46.95% | 0.02% | 16.14% | 8.06% | -3.65% | 3.34% | 13.92% | 5.95% | 19.42% |
GSK GSK plc | 7.22% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -17.72% | 29.24% | 13.79% | -2.97% |
Correlation
The correlation between NVS and GSK is 0.69, which is moderate. They have sometimes moved together and sometimes differently, sharing some price drivers without tracking each other closely.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.69 |
Correlation (3Y) Balances recent behavior with more history. | 0.60 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.58 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.57 |
Correlation (All Time) Calculated using the full available price history since Nov 7, 1996 | 0.50 |
The correlation between NVS and GSK shifts across timeframes, from 0.50 (all time) to 0.69 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
NVS:
$296.80B
GSK:
$103.56B
NVS:
$6.63
GSK:
£2.36
NVS:
23.56
GSK:
16.25
NVS:
1.59
GSK:
0.36
NVS:
5.40
GSK:
2.36
NVS:
7.19
GSK:
4.45
NVS:
$55.63B
GSK:
£33.25B
NVS:
$41.41B
GSK:
£24.35B
NVS:
$22.26B
GSK:
£10.68B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVS vs. GSK — Risk / Return Rank
NVS
GSK
NVS vs. GSK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Novartis AG (NVS) and GSK plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVS | GSK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.25 | ||
| Sortino ratioReturn per unit of downside risk | +0.23 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 1.29 | +0.04 |
| Calmar ratioReturn relative to maximum drawdown | 3.29 | 2.41 | +0.89 |
| Martin ratioReturn relative to average drawdown | 7.73 | 5.24 | +2.50 |
Loading charts...
Drawdowns
NVS vs. GSK - Drawdown Comparison
The maximum NVS drawdown since its inception was -42.10%, smaller than the maximum GSK drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for NVS and GSK.
Loading charts...
Drawdown Indicators
| NVS | GSK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -42.10% | -55.70% | +13.60% |
Max Drawdown (1Y)Largest decline over 1 year | -12.65% | -18.53% | +5.88% |
Max Drawdown (3Y)Largest decline over 3 years | -19.95% | -28.46% | +8.51% |
Max Drawdown (5Y)Largest decline over 5 years | -20.42% | -50.10% | +29.68% |
Max Drawdown (10Y)Largest decline over 10 years | -26.03% | -50.10% | +24.07% |
Current DrawdownCurrent decline from peak | -4.58% | -14.05% | +9.47% |
Average DrawdownAverage peak-to-trough decline | -10.90% | -18.85% | +7.95% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.38% | 8.49% | -3.11% |
Volatility
NVS vs. GSK - Volatility Comparison
The current volatility for Novartis AG (NVS) is 7.89%, while GSK plc (GSK) has a volatility of 8.74%. This indicates that NVS experiences smaller price fluctuations and is considered to be less risky than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVS | GSK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.89% | 8.74% | -0.85% |
Volatility (6M)Calculated over the trailing 6-month period | 16.05% | 19.87% | -3.82% |
Volatility (1Y)Calculated over the trailing 1-year period | 21.74% | 26.94% | -5.20% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 19.28% | 25.39% | -6.11% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 19.73% | 22.97% | -3.24% |
Dividends
NVS vs. GSK - Dividend Comparison
NVS's dividend yield for the trailing twelve months is around 3.06%, less than GSK's 3.47% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GSK plc | 3.47% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
NVS Novartis AG | 3.06% | 2.90% | 3.84% | 3.44% | 3.70% | 3.86% | 3.22% | 3.03% | 3.47% | 3.24% | 3.73% | 3.10% |
Financials
NVS vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Novartis AG and GSK plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVS vs. GSK - Profitability Comparison
NVS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Novartis AG reported a gross profit of 10.74B and revenue of 14.42B. Therefore, the gross margin over that period was 74.5%.
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, GSK plc reported a gross profit of 6.34B and revenue of 8.45B. Therefore, the gross margin over that period was 75.1%.
NVS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Novartis AG reported an operating income of 4.74B and revenue of 14.42B, resulting in an operating margin of 32.8%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, GSK plc reported an operating income of 2.41B and revenue of 8.45B, resulting in an operating margin of 28.5%.
NVS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Novartis AG reported a net income of 3.27B and revenue of 14.42B, resulting in a net margin of 22.7%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, GSK plc reported a net income of 437.26M and revenue of 8.45B, resulting in a net margin of 5.2%.
Frequently Asked Questions
NVS and GSK have a correlation of 0.69, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GSK has higher volatility (8.74%) compared to NVS (7.89%). In terms of maximum drawdown, NVS dropped -42.10% vs GSK's -55.70%.
NVS currently has the higher Sharpe Ratio (1.93 vs 1.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVS and GSK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer